source
- Moderna and Merck’s mRNA success fuels focus on ‘scaling out and scaling down’After mastering mass-market mRNA production during the pandemic, the industry now needs to achieve the timely delivery of individualized vaccines to thousands of patients.BioSpace · 15m ago↗ source
- Reeling from past failures, Parkinson's pipeline enters 'era of diversification'While some drugmakers continue to walk the alpha-synuclein antibody path, others like AC Immune opt for new approaches that could bring the first-ever disease-modifying therapy for Parkinson's dise…BioSpace · 21m ago↗ source
- Novo Nordisk abandons two phase 3 trials of ziltivekimab, dimming blockbuster hopesNovo Nordisk announced it is terminating two late‑stage phase 3 studies of its IL‑6 ligand antibody ziltivekimab. The Hermes and Athena trials enrolled about 4,900 and 673 patients with heart fail…